Navigation Links
Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
Date:9/25/2007

SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive preliminary results from its Phase 2 clinical trial of APD125 in patients with chronic insomnia. APD125 is an orally available drug candidate discovered by Arena that is being evaluated in insomnia patients who have difficulty maintaining sleep after initial sleep onset. When compared to placebo, patients treated with APD125 experienced statistically significant improvements in measurements of sleep maintenance, or the ability to maintain sleep during the night after falling asleep. The improvements in measurements of sleep maintenance were achieved without any limiting next day cognitive effects. The data from the APD125 Phase 2 study are consistent with Phase 1 data and support further development of APD125 for the treatment of insomnia patients who have difficulty maintaining sleep.

"APD125 clearly has robust sleep maintenance properties," according to Dr. Thomas Roth of Henry Ford Hospital, who interpreted the polysomnography data for the Phase 2 trial. "In the trial, APD125 consolidated sleep in ways that are not accomplished by any currently available drug."

The Phase 2 trial of APD125 was a randomized, double-blind, placebo- controlled study evaluating the safety and efficacy of nighttime dosing in patients with chronic insomnia. The trial evaluated standard measurements of sleep, such as wake after sleep onset (WASO), wake time during sleep (WTDS), number of awakenings, number of arousals, total sleep time and latency to persistent sleep, and enrolled a total of 173 male and female patients in about 25 clinical sites in the United States. The trial employed a cross-over design: every pa
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)...  EP Global Communications, Inc. (Public OTC: EPGL) announced today ... Company about discussing EPGL,s electronic contact lens technologies.  ... 3, 2015.  Novartis CEO Joe Jimenez ... electronic contact lens market could be worth tens ... years.  Novartis partnered with Google in 2014 to ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm ... it has acquired a majority interest in Salter Labs ... a leading manufacturer of disposable respiratory and sleep diagnostics ... care markets.   "Salter represents an exciting ...
... Talecris Biotherapeutics (Nasdaq: TLCR ) announced ... Inhibitor [Human])(A1PI), a more concentrated and purified formulation of ... Canada for more than 20 years.  PROLASTIN-C delivers twice ... infusion volume and time in half when given at ...
Cached Medicine Technology:RoundTable Healthcare Partners Acquires Majority Stake in Salter Labs 2RoundTable Healthcare Partners Acquires Majority Stake in Salter Labs 3Talecris Biotherapeutics Launches PROLASTIN®-C in Canada 2Talecris Biotherapeutics Launches PROLASTIN®-C in Canada 3Talecris Biotherapeutics Launches PROLASTIN®-C in Canada 4Talecris Biotherapeutics Launches PROLASTIN®-C in Canada 5
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that it is ... campus. The goal is to bring this Torah – dating from 1880 – back ... and religious services. , Scroll No. 515, from the town of Taus-Domazlice, is ...
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the network ... their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been ... companies have agreed to join their missions of purpose together to change the course ...
(Date:8/1/2015)... , ... August 01, 2015 , ... On Tuesday, July ... , who are thought to have been behind the attack on Anthem Inc. which ... were zero day exploits, watering hole attacks and spear phishing campaigns. , ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe ... the very first small business donation to kick off the campaign for healing and ... Her legacy includes a complete line of raw, organic hair care products, as well ...
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, Phil ... reached Connecticut and was greeted by friends and family. He visited CCAR and left ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:March4thforWellBeing Foundation Kickoff 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... begun full-parity plans ahead of deadline; new case studies ... reports the majority of its customers are revamping their ... Act, and that a significant amount already have gone ... 1, 2010. ComPsych Corporation is the world,s largest provider ...
... University of Leeds are working on a new type of body ... cement with recycled carbon fibre materials to make a material tough ... project, still at the early research stage, is being carried out ... Philip Purnell, who is leading the team, said: "By using cement ...
... Improves Patient Care with Automatic Access to Radiology Reports ... a division of Conceptual MindWorks, Inc. (CMI), today announced ... Radiological Association,s (ARA) radiology reports. ARA is one of ... operates 14 outpatient radiology clinics in addition to providing ...
... Innovative new concept caters to active baby-boomer retirees , ... of America (ORCA) has started taking reservations for a program ... private residential cruise ship that also provides both the Independent ... , "People retire to Florida for three things mainly ...
... , CHICAGO, June 29 Rising Financial ... of Rising Medical Solutions, Inc., is pleased to announce ... Business Development for its Medicare Set Aside (MSA) Administration ... , , Abdelsayed joins Rising Financial Solutions (Rising) ...
... , Italy, June 29 Health-Robotics today announced,that ... with Grifols,S.A., the leading Pharmacy Automation provider in ... accurately, and cost-effectively automate,the preparation of non-hazardous IV ... this strategic partnership, Grifols will take,delivery of 120 ...
Cached Medicine News:Health News:Mental Health Parity Act Spurs Early Action Among Employers 2Health News:Sevocity Launches EHR (Electronic Health Record) Interface With Austin Radiological Association 2Health News:Sevocity Launches EHR (Electronic Health Record) Interface With Austin Radiological Association 3Health News:Retirement Cruise Ship Nearing Launch 2Health News:Rising Financial Solutions Taps Director of Business Development for Medicare Set Aside Administration Offerings 2Health News:Health Robotics Announces i.v.STATION(TM) Contract With Grifols in Spain, Portugal and South America 2Health News:Health Robotics Announces i.v.STATION(TM) Contract With Grifols in Spain, Portugal and South America 3
... Nephew ECTRA II systems permit the surgeon ... ligament endoscopically, allowing access via two portals ... endoscopic lens fogging with good air flow. ... and control. ECTRA knives permit the surgeon ...
... Screw System provides a unique option for the ... particularly the opening wedge osteotomy of the first ... Fragment Plate and Screw Set is a complete ... houses the plates, screws, and drills. It provides ...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Medicine Products: